skip to primary navigationskip to content
 

Semarion

semarion

Semarion has been founded by Tarun Vemulkar (c2012) and Jeroen Verheyen (a2014). Tarun and Jeroen won the NanoDTC Translational Prize to jointly develop the technology that led to the formation of Semarion.

Semarion’s mission is to triple the success rate of clinical trials by providing novel in-depth protein fingerprint insight into a patient’s state of health.

Drug development suffers from high failure rates during clinical trial phases 2 (70%) and 3 (50%) which can be overcome by patient stratification and precision medicine. Mass spectroscopy (protein fingerprints) and low-biomarker assays (1-3 proteins) have been used to identify high response patient populations. These technologies are, however, not scalable or give minimal insight. Further, genomic tools cannot provide the same level of insight into a patient’s state of health and disease.

Semarion’s proteomics platform uses novel magnetic nanoparticles with highly tuneable magnetic, optical, and surface properties. This allows the Semarion platform to simultaneously quantify 1,000s of proteins in small samples, in an accurate, affordable, and automated way.

Semarion will provide tools and services to pharma companies and clinical research organisations. Our technology can enable high-level patient stratification while generating additional data on efficacy, toxicity, off-target effects, and new drug targets.